5 Best Biotech Stocks for 2026 and How to Invest


Biotech stocks focus on companies developing new and previously unimaginable ways to treat and prevent diseases. Many of the strongest players pair promising drug pipelines with successful treatments already on the market.

Some scientists believe that we’re in the golden age of biotechnology. If you’re looking to invest in this fast-moving space, a few biotech stocks stand out right now.

5 top biotech stocks for 2026

The top biotech stocks right now include well-established players that dominate their markets, as well as rising stars. These biotech companies focus on different diseases and use different approaches, but they all have promising long-term growth potential.

Data as of Nov 18, 2026. Showing 5 of 5 total entries.

1. Axsome Therapeutics

AXSM Axsome Therapeutics

$135.95-$1.06 (-0.77%)

NASDAQ · As of 4:00 PM ET 11/17/26

Axsome‘s (AXSM -0.77%) revenue is soaring thanks to strong momentum for two drugs — Auvelity and Sunosi. The company launched Auvelity in October 2022 as a treatment for major depressive disorder. It acquired sleep disorder drug Sunosi from Jazz Pharmaceuticals (JAZZ +0.39%) in May 2022.

In January 2025, Axsome added a third product to its lineup with the U.S. Food and Drug Administration (FDA) approval of Symbravo for treating migraines. The drug could have significant commercial potential, with current migraine therapies not as effective as desired for many patients.

On April 30, 2026, the FDA approved Axsome’s Auvelity for the treatment of agitation in Alzheimer’s disease. Axsome also awaits FDA approval of AXS-12 for the treatment of narcolepsy by May 1, 2027.

2. BioNTech

BNTX BioNTech Se

$84.86-$0.40 (-0.47%)

NASDAQ · As of 4:00 PM ET 11/17/26

BioNTech (BNTX -0.47%) hit the jackpot with its 2020 collaboration with Pfizer (PFE -1.35%) to develop a COVID-19 vaccine. Although sales of Comirnaty, the vaccine that the two partners market together, have fallen since the end of the COVID-19 pandemic, BioNTech now has a huge cash stockpile as a result of the vaccine’s success.

The German biotech innovator is still developing new vaccines to fight viruses. It’s evaluating a combination flu-COVID vaccine in Phase 1/2 testing in collaboration with Pfizer. The company also has other experimental vaccines in its pipeline targeting malaria, Herpes Simplex Virus (HSV), and tuberculosis.

However, BioNTech’s big opportunity is in treating cancer. The company’s pipeline includes more than 25 phase 2 and phase 3 clinical trials targeting various cancer types.

3. Exelixis

EXEL Exelixis

$68.50+$1.40 (+2.09%)

NASDAQ · As of 4:00 PM ET 11/17/26

Exelixis (EXEL +2.09%) has developed four drugs that are already on the market. Its biggest winner, by far, is Cabometyx, which is approved to treat renal cell carcinoma (RCC) and hepatocellular carcinoma (HC) — the most common types of kidney cancer and liver cancer, respectively — as well as thyroid cancer.

Exelixis and big drugmaker Bristol Myers Squibb (BMY -2.51%) won U.S. regulatory approval in early 2021 for the use of Cabometyx in combination with Bristol Myers’ immunotherapy drug Opdivo. The company is also evaluating Cabometyx in combination with other drugs in late-stage studies targeting several types of cancer.

The next major growth driver for Exelixis could be zanzalintinib. The FDA is scheduled to make an approval decision on the drug in combination with Roche‘s (NASDAQOTH:RHHBY) Tecentriq for previously treated metastatic colorectal cancer by March 3, 2027.

4. Mirum Pharmaceuticals

MIRM Mirum Pharmaceuticals

$91.95+$0.37 (+0.40%)

NASDAQ · As of 4:00 PM ET 11/17/26

Mirum Pharmaceuticals‘ (MIRM +0.40%) flagship product, Livmarli, is approved in the U.S. for the treatment of liver diseases where bile flow is blocked or impeded. The drug continues to deliver strong sales growth. Mirum also markets two other products, Cholbam and Ctexli.

The company in-licensed ziligurgisertib from Incyte (INCY -0.98%) in May 2026. The FDA is scheduled to make an approval decision for the drug to treat fibrodysplasia ossificans progressiva, a rare genetic disorder, by Sept. 26, 2026.

Mirum’s pipeline also features two particularly promising candidates, volixibat and brelovitug. Volixibat met the primary endpoint of a Phase 2b study targeting primary sclerosing cholangitis, a rare chronic liver disease. Mirum expects to file for FDA approval in the first half of 2027. Brelovitug also met the primary endpoint of a Phase 2b study for the treatment of chronic hepatitis delta virus.

5. Vertex Pharmaceuticals

VRTX Vertex Pharmaceuticals

$534.20-$3.59 (-0.67%)

NASDAQ · As of 4:00 PM ET 11/17/26

Vertex (VRTX -0.67%), which makes multiple cystic fibrosis (CF) drugs, enjoys a monopoly over sales of treatments for the underlying cause of CF. Its dominance in CF was bolstered by the December 2024 approval of Alyftrek.

CF isn’t Vertex’s only market now, though. The big biotech company is ramping up commercialization efforts for Casgevy, a gene-editing therapy approved to treat two rare blood disorders — sickle cell disease and transfusion-dependent beta-thalassemia.

Vertex also won FDA approval in January 2025 for Journavx (suzetrigine). This non-opioid drug is the first new type of pain medication approved in more than 20 years.

The big drugmaker completed its acquisition of Crinetics Pharmaceuticals in September 2026. This deal adds another product to Vertex’s lineup — Parsonify, which is approved in the U.S. and the European Union for treating acromegaly, a rare hormonal disorder.

The company awaits accelerated approval for povetacicept in treating chronic kidney disorder IgA nephropathy. Vertex’s pipeline also includes other promising candidates, including inaxaplin, which targets APOL1-mediated kidney disease.

How to buy biotech stocks

The following are key steps to take to invest in biotech stocks:

  1. Open your brokerage app: Log in to your brokerage account where you handle your investments. If you don’t have one yet, take a look at our favorite brokers and trading platforms to find the right one for you.
  2. Search for your biotech stock: Enter the ticker or company name into the search bar to bring up the stock’s trading page.
  3. Decide how many shares to buy: Consider your investment goals and how much of your portfolio you want to allocate to this stock.
  4. Select order type: Choose between a market order to buy at the current price or a limit order to specify the maximum price you’re willing to pay.
  5. Submit your order: Confirm the details and submit your buy order.
  6. Review your purchase: Check your portfolio to ensure your order was filled as expected and adjust your investment strategy accordingly.

Benefits and risks of investing in biotech stocks

The benefits of investing in biotech stocks include:

  • Significant growth potential
  • Portfolio diversification with low correlation with the overall market
  • An opportunity to invest in the development of potentially life-saving treatments

However, there are also risks associated with investing in biotech stocks, including:

  • The potential for clinical trial failures
  • The potential for regulatory setbacks
  • Competitive threats

Methodology: How these stocks were chosen

The obvious criterion for choosing these stocks was that they had to operate in the biotech industry. Size mattered, too. Only stocks with market caps of at least $200 million were considered.

Most importantly, though, the growth prospects for each stock were evaluated. Although projecting growth for any biotech company is challenging given the inherent risks of drug development, all five of these stocks appear to have strong growth potential.

Should you invest in biotech stocks?

Reasons to invest in biotech stocks include:

  • Biotech stocks offer the potential for significant returns.
  • Some biotech companies have strong financial positions, which lowers their risk.
  • Biotech stocks can perform well even when the overall stock market doesn’t.

On the other hand, reasons you might not want to invest in biotech stocks include:

  • Biotech companies’ drug candidates can prove ineffective, or even worse, in clinical testing.
  • There’s no guarantee that pipeline candidates will win regulatory approvals.
  • Even if a biotech company’s drug wins approval, it might not be successful commercially.
  • Small clinical-stage biotech companies might have to dilute their shareholders’ holdings by issuing new stock to raise cash.

Related investing topics

Biotech stocks FAQ

Keith Speights has positions in Bristol Myers Squibb, Pfizer, and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Axsome Therapeutics, Bristol Myers Squibb, Exelixis, Incyte, Mirum Pharmaceuticals, Pfizer, and Vertex Pharmaceuticals. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy.

Leave a Reply

Your email address will not be published. Required fields are marked *